Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue

被引:20
作者
Mak, Lung-Yi [1 ]
Lee, Chi-Ho [1 ,2 ]
Cheung, Ka-Shing [1 ]
Wong, Danny Ka-Ho [1 ,3 ]
Liu, Fen [1 ]
Hui, Rex Wan-Hin [1 ]
Fung, James [1 ,3 ]
Xu, Aimin [1 ,4 ,5 ]
Lam, Karen Siu-Ling [1 ]
Yuen, Man-Fung [1 ,3 ]
Seto, Wai-Kay [1 ,3 ,6 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[2] Univ Hong Kong, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Peoples R China
[3] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China
[4] Univ Hong Kong, Dept Pharmacol & Pharm, Hong Kong, Peoples R China
[5] Univ Hong Kong, State Key Lab Pharmaceut Biotechnol, Hong Kong, Peoples R China
[6] Univ Hong Kong, Dept Med, Shenzhen Hosp, Shenzhen, Peoples R China
关键词
chronic hepatitis B; fatty liver disease; liver fibrosis; nucleoside analogues; NONALCOHOLIC FATTY LIVER; ACID-BINDING PROTEIN; GROWTH-FACTOR; 21; ADIPOSE-SPECIFIC PROTEIN; HEPATOCELLULAR-CARCINOMA; INSULIN-RESISTANCE; DISEASE; ADIPONECTIN; STEATOHEPATITIS; INCREASES;
D O I
10.1111/liv.14104
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims It is unknown how concomitant hepatic steatosis affects disease progression in chronic hepatitis B (CHB). Adipokines such as fibroblast growth factor 21 (FGF21) and adipocyte fatty acid-binding protein (AFABP) have been associated with non-alcoholic fatty liver disease. We determined the significance of these metabolic markers in CHB-related liver injury. Methods We recruited CHB patients on antiviral treatment for transient elastography assessment to determine liver stiffness (advanced fibrosis/cirrhosis, F3/F4, defined by EASL-ALEH criteria) and controlled attenuation parameter (hepatic steatosis, defined as >= 248 dB/m). Plasma FGF-21, AFABP and adiponectin levels were measured. Results A total of 415 patients [mean age 59.6 years, 71.6% male, median treatment duration 6.2 years] were recruited. Patients with F3/F4 (N = 151) had lower FGF-21 (11.7 vs 13.6 pg/mL, P = 0.055), higher AFABP (126.8 vs 84.1 pg/mL, P < 0.001) and HOMA-IR (7.1 vs 5.1, P = 0.004) levels compared to those without F3/F4 (N = 264). Multivariate analysis showed that FGF-21 level was associated with hepatic steatosis (OR 1.005, 95% CI 1.001-1.009) and F3/F4 (OR 0.993, 95% CI 0.989-0.998), while AFABP level (OR 1.001, 95% CI 1-1.002), body mass index (BMI) (OR 1.107, 95% CI 1.037-1.182) and presence of diabetes mellitus (OR 2.059, 95% CI 1.206-3.516) were associated with F3/F4. With the combined presence of BMI >= 25 kg/m(2), diabetes and AFABP > 105.9 pg/mL, the odds ratio for F3/F4 was 3.712 (95% CI 1.364-10.105, P = 0.010). Conclusions Low FGF-21 and high AFABP levels were associated with advanced fibrosis/cirrhosis in CHB patients on antiviral treatment. Plasma AFABP, together with other metabolic risk factors, may aid identification of patients lacking fibrosis improvement during antiviral treatment.
引用
收藏
页码:1217 / 1225
页数:9
相关论文
共 50 条
[1]  
[Anonymous], 2015, J HEPATOL, DOI DOI 10.1016/j.jhep.2015.04.006
[2]   Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].
Arita, Y ;
Kihara, S ;
Ouchi, N ;
Takahashi, M ;
Maeda, K ;
Miyagawa, J ;
Hotta, K ;
Shimomura, I ;
Nakamura, T ;
Miyaoka, K ;
Kuriyama, H ;
Nishida, M ;
Yamashita, S ;
Okubo, K ;
Matsubara, K ;
Muraguchi, M ;
Ohmoto, Y ;
Funahashi, T ;
Matsuzawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83
[3]   Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? [J].
Asrih, Mohamed ;
Jornayvaz, Francois R. .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 418 :55-65
[4]   Impact of non-alcoholic fatty liver disease on chronic hepatitis B [J].
Bondini, Silvia ;
Kallman, Jillian ;
Wheeler, Angela ;
Prakash, Shivaani ;
Gramlich, Terry ;
Jondle, Daniel M. ;
Younossi, Zobair M. .
LIVER INTERNATIONAL, 2007, 27 (05) :607-611
[5]   Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis [J].
Boord, JB ;
Fazio, S ;
Linton, MF .
CURRENT OPINION IN LIPIDOLOGY, 2002, 13 (02) :141-147
[6]   Insulin resistance: A metabolic pathway to chronic liver disease [J].
Bugianesi, E ;
McCullough, AJ ;
Marchesini, G .
HEPATOLOGY, 2005, 42 (05) :987-1000
[7]   Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up [J].
Ekstedt, Mattias ;
Hagstrom, Hannes ;
Nasr, Patrik ;
Fredrikson, Mats ;
Stal, Per ;
Kechagias, Stergios ;
Hultcrantz, Rolf .
HEPATOLOGY, 2015, 61 (05) :1547-1554
[8]   Hepatocellular carcinoma in cirrhosis: Incidence and risk factors [J].
Fattovich, G ;
Stroffolini, T ;
Zagni, I ;
Donato, F .
GASTROENTEROLOGY, 2004, 127 (05) :S35-S50
[9]   Mild-to-Moderate Elevation of Alanine Aminotransferase Increases Liver Stiffness Measurement by Transient Elastography in Patients With Chronic Hepatitis B [J].
Fung, James ;
Lai, Ching-Lung ;
Cheng, Charles ;
Wu, Ringo ;
Wong, Danny Ka-Ho ;
Yuen, Man-Fung .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (03) :492-496
[10]   Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes [J].
Graupera, Isabel ;
Coll, Mar ;
Pose, Elisa ;
Elia, Chiara ;
Piano, Salvatore ;
Sola, Elsa ;
Blaya, Delia ;
Huelin, Patricia ;
Sole, Cristina ;
Moreira, Rebeca ;
de Prada, Gloria ;
Fabrellas, Nuria ;
Juanola, Adria ;
Morales-Ruiz, Manuel ;
Sancho-Bru, Pau ;
Villanueva, Candid ;
Gines, Pere .
SCIENTIFIC REPORTS, 2017, 7